Combined chemo-endocrine adjuvant therapy for patients with operable breast cancer: Still a question?

This publication has 27 references indexed in Scilit:

• Tamoxifen and Chemotherapy for Lymph Node-Negative, Estrogen Receptor-Positive Breast Cancer
  JNCI Journal of the National Cancer Institute, 1997
• Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. Breast Cancer Site Group.
  Journal of Clinical Oncology, 1997
• Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients.
  Journal of Clinical Oncology, 1997
• Adjuvant Chemo-Endocrine Therapy or Endocrine Therapy Alone for Postmenopausal Patients: Ludwig Studies III and IV
  Published by Springer Nature ,1989
• Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer
  British Journal of Cancer, 1988
• A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. The Australian and New Zealand Breast Cancer Trials Group, Clinical Oncological Society of Australia.
  Journal of Clinical Oncology, 1986
• Randomized trial of 3 different regimens of combination chemotherapy in patients receiving simultaneously a hormonal treatment for advanced breast cancer
  European Journal of Cancer and Clinical Oncology, 1983
• Treatment of Primary Breast Cancer with Chemotherapy and Tamoxifen
  New England Journal of Medicine, 1981
• Combination Chemotherapy as an Adjuvant Treatment in Operable Breast Cancer
  New England Journal of Medicine, 1976
• Surgical Adjuvant Chemotherapy in Cancer of the Breast
  Annals of Surgery, 1968